S&P Futures
4,371.50 +10.50 (+0.24%) Dow Futures
34,302.00 +70.00 (+0.20%) Nasdaq Futures
14,917.50 +48.00 (+0.32%) Russell 2000 Futures
1,799.40 +6.70 (+0.37%) Crude Oil
90.23 +0.20 (+0.22%) Gold
1,943.00 -2.60 (-0.13%)
Insmed Incorporated (INSM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 26.34 |
| Open | 26.49 |
| Bid | 24.99 x 800 |
| Ask | 26.77 x 1400 |
| Day's Range | 25.75 - 26.52 |
| 52 Week Range | 16.04 - 27.59 |
| Volume | |
| Avg. Volume | 1,301,462 |
| Market Cap | 3.763B |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.43 |
| Earnings Date | Oct 25, 2023 - Oct 30, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.58 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for INSM
Related Research
- Insmed IncorporatedDaily – Vickers Top Buyers & Sellers for 11/03/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat11 months agoArgus Research
Motley FoolWhy Shares of Insmed Are Soaring This Week
Shares of Insmed (NASDAQ: INSM) were up more than 17% for the week as of 10:30 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. On Tuesday, Insmed reported positive top-line results from its Phase 3 study of Arikayce to treat patients (who had not started antibiotics) with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC). There are no established endpoints to evaluate MAC treatments, and Insmed said it is hoping the Food and Drug Administration (FDA) will adopt its Quality of Life-Bronchiectasis measurement.
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 13 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- PR Newswire
Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, on Monday, September 11, 2023 at 2:55 p.m. ET.
